admin

April 19, 2022 12:00 UTC   — Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies — Scalable and Adaptable Facility Provides Flexibility for Current and Future Cell Therapy Innovation   SANTA MONICA, Calif.–(BUSINESS WIRE)– Kite Pharma, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved commercial production at the company’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer.  

Did you hear? Our second BLUE KNIGHT™ Symposium will take place June 9, 2022, and we’re excited to present your first chance to register! Tune in virtually from wherever you are around the world for a day of live programming. This year’s theme, The Power of Partnering to Accelerate Preparedness, aims to answer the questions startups have around accelerating innovations and earning a seat at the global preparedness table.

We echo that theme in today’s exclusive Q&A with Dr. David Boucher of ASPR and Dr. Karen Martins of BARDA, on the power of collaboration to build global resiliency toward health security threats. These experts share advice for early-stage companies and explore their experiences partnering to move “faster and better”. Read more here.

LEIDEN, The Netherlands, April 14, 2022 – MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund.

Oncode Institute will lead the Oncode-PACT consortium and its operations. With this investment, the consortium will develop cancer drug candidates faster and bring them to patients sooner. As a partner in Oncode-PACT, MIMETAS will develop the next generation of patient-specific cancer organoid models that include immune cells, blood vessels, and other essential cell types to drive novel cancer drug discovery and developm ent. Using these models, MIMETAS will screen compounds and targets using fully integrated, automatic phenotypic screening lines with AI data interpretation, bringing early validation and de-risking to the cancer drug development pipeline.

Image: https://www.mimetas.com

Please join the inaugural webcast “Tell Me Something I Don’t Know,” hosted by Children’s National Hospital (CNH) Innovation Ventures and the National Capital Consortium for Pediatric Device Innovation (NCC-PDI). In this episode, we learn about the process of selecting novel technologies for implementation at CNH. Jennifer Yin, MSN, RN, CVAHP, hospital’s Value Analysis Clinical Program Manager, will engage in a fireside chat with Francesca Joseph, MD, FAAP, Pediatrician at CNH and co-Investigator of NCC-PDI. Jennifer and Francesca will provide a general understanding of the Value Analysis process and highlight topics most relevant to medical device innovators.

A new 500,000 square-foot life science campus is being planned for Frederick County.

With two 100,000 square-foot research and development labs; two additional 145,000 square-foot production buildings; co-working space; conference rooms; and more, The Labs at Jefferson Tech Park will provide in demand, state-of-the-art space for life science companies looking to locate along the I-270 corridor.

The campus – which aims to be the “premier biodiscovery campus” in the county – is also expected to host numerous fitness and walking trails, outdoor green space, a cafe, and plenty of parking.

Individuals from diverse backgrounds can provide unique and valuable contributions in the research and development of life science innovations that prevent disease, prolong life, and promote health. However, certain groups, such as women and individuals from racial/ethnic minoritized groups, remain underrepresented in the U.S. biomedical sciences and in life science entrepreneurship.

Today, I am pleased to introduce the inaugural cohort of the NIH 21st Century Scholars Program—a new COSWD-sponsored initiative to promote awareness of the science of scientific workforce diversity. Six mentors and 13 cohort engagement participants from the NIH extramural scientific workforce were selected; together, they will build a vibrant, self-reinforcing culture of mentoring and support with a focus on diversity at the NIH.

ANNAPOLIS, MD—Governor Larry Hogan today announced a new Maryland Cancer Moonshot Initiative to expand and accelerate cancer detection, screening, prevention, treatment, and research in the state. The state is committing $216 million in investments as a down payment to jumpstart this far-reaching initiative to save lives, including the first ever comprehensive cancer center in Prince George’s County.

Image: https://governor.maryland.gov/

The NasaClip device provides simple and effective nosebleed rescue at home or anywhere, using hands-free, external nasal compression with intranasal sponges that medicine can be added to – helping to stop nosebleeds fast.

Image: https://www.tedcomd.com